About Quellis Biosciences
Quellis Biosciences is a company based in Boston (United States) founded in 2017 by Vahe Bedian and Jonathan Violin was acquired by Astria in January 2021. Quellis Biosciences has raised $17 million across 2 funding rounds from investors including Astria Therapeutics and Xontogeny. Quellis Biosciences operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Boston, United States
- Founders Vahe Bedian, Jonathan Violin
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$17 M (USD)
in 2 rounds
-
Latest Funding Round
$17 M (USD), Series A
Dec 10, 2019
-
Investors
Astria Therapeutics
& 1 more
-
Employee Count
Not available
-
Acquired by
Astria
(Jan 29, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Quellis Biosciences
Quellis Biosciences has successfully raised a total of $17M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $17 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Quellis Biosciences
Quellis Biosciences has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Astria Therapeutics and Xontogeny.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life science startups are accelerated through focused programs by Xontogeny.
|
Locked | Locked | Locked | |
|
Therapeutics for rare diseases, including hereditary angioedema inhibitors, are developed.
|
Locked | Locked | Locked |
Investor details for Quellis Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Quellis Biosciences
Investment portfolio details for Quellis Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Quellis Biosciences
Detailed financials for Quellis Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Quellis Biosciences Comparisons
Peer comparison for Quellis Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Quellis Biosciences
Quellis Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
Detailed competitors of Quellis Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Quellis Biosciences
Complete news archive for Quellis Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Quellis Biosciences
Quellis Biosciences was founded in 2017.
Quellis Biosciences is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Quellis Biosciences is a funded company, having raised a total of $17M across 2 funding rounds to date.
Quellis Biosciences was established in 2017 in Boston, United States, within the biotechnology sector. Monoclonal antibodies targeting rare diseases are developed and refined. Xtend technology is employed to extend antibody half-life and minimize dosing frequency. Focus is placed on antibody-based drug development, with operations conducted from the companys location in the United States.
Quellis Biosciences's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Quellis Biosciences has 2 investors. Key investors include Astria Therapeutics, and Xontogeny.